<DOC>
	<DOCNO>NCT01777412</DOCNO>
	<brief_summary>This phase 1b interventional trial bevacizumab ( Avastin® ) evaluate tolerability/safety preliminary efficacy bevacizumab ( Avastin® ) add-on therapy treatment acute optic neuritis and/or transverse myelitis neuromyelitis optica ( NMO ) neuromyelitis optica spectrum disorder ( NMOSD ) . A single infusion Avastin® add standard-of-care high dose steroid additional dose Avastin® add plasma exchange ( necessary ) . The primary outcome clinical change Expanded Disability Severity Scale , Timed 25-foot Walk Low Contrast Visual Acuity , MRI parameter safety .</brief_summary>
	<brief_title>Efficacy Bevacizumab ( Avastin ) Treatment Acute NMO Exacerbations</brief_title>
	<detailed_description>Study Objective : The overall objective evaluate tolerability/safety efficacy add bevacizumab ( Avastin® ) standard care therapy improve clinical radiologic outcome acute optic neuritis and/or transverse myelitis neuromyelitis optica neuromyelitis optica spectrum disorder . Primary Objective : To compare clinical radiographic outcome follow acute optic neuritis and/or transverse myelitis NMO/NMOSD patient receive 1-2 dos 10 mg/kg dose bevacizumab ( Avastin® ) addition standard medical therapy . Secondary Objectives : - To determine effect Avastin NMO clinical score ( Expanded Disability Status Scale , Timed 25-foot Walk Low Contrast Visual Acuity [ LCVA ] ) . - To evaluate safety tolerability 10 mg/kg dose intravenous Avastin . - To determine frequency adverse event Avastin patient population . - To determine effect Avastin MRI lesion size extent . The duration investigation 1-2 year .</detailed_description>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Subjects eligible enrollment must meet following criterion : 1 . Able willing provide write informed consent . 2 . 1870 year age . 3 . New acute optic neuritis and/or transverse myelitis . A clinical event define episode inflammation spinal cord and/or optic nerve lead neurologic symptom ascribe another disease process . 4 . Known suspected diagnosis NMO accord 2006 revision Wingerchuk diagnostic criterion NMO AQP4 positive NMOSD per EFNS Guidelines . For NMO , subject must two absolute criterion : 1. optic neuritis 2. myelitis least two three supportive criterion : 3. presence contiguous spinal cord MRI lesion extend three vertebral segment , 4 . MRI criterion NOT satisfy revise McDonald diagnostic criterion MS [ Polman , 2011 ] 5 . NMOIgG ( AQP4 ) serum . For NMOSD , subject must longitudinally extensive transverse myelitis ( LETM ) recurrent isolate optic neuritis ( RION ) /bilateral optic neuritis ( BON ) , opticospinal multiple sclerosis ( OSMS ) AQP4 antibody positive 5 . A female subject eligible enter study : A . Not pregnant nursing ; B . Of nonchildbearing potential ( i.e . woman hysterectomy , postmenopausal , define &gt; 2 year without menses ( female subject postmenopausal &lt; 2 year must confirm Follicle Stimulating Hormone ( FSH ) estradiol level ) , ovaries surgically remove current document tubal ligation ) ; , C. Of childbearing potential ( i.e . woman functional ovary document impairment oviductal uterine function would cause sterility ) . This category include woman oligomenorrhoea ( even severe ) , woman perimenopausal begin menstruate . The subject must negative serum pregnancy test screen agree one following : . Complete abstinence intercourse period consent study 6 month last dose investigational product ; , ii . Consistent correct use one follow acceptable method birth control period consent study 6 month last dose investigational product : 1 . Oral contraceptive ( either combine progesterone ) 2 . Injectable progesterone 3 . Levonorgestrel implant 4 . Estrogenic vaginal ring 5 . Percutaneous contraceptive patch 6 . Intrauterine device ( IUD ) intrauterine system ( IUS ) document failure rate &lt; 1 % per year 7 . Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study ; male must sole partner subject 8 . Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) . Subjects meet follow criterion eligible enroll study : 1 . Evidence history clinically significant infection include : 1 . Chronic ongoing active infectious disease require long term systemic treatment , limited : PML , chronic renal infection , chronic chest infection bronchiectasis , tuberculosis , active hepatitis C. 2 . Positive test HBsAg . 3 . Prior history , suspicion , tuberculosis ( TB ) 4 . History positive serology HIV . 2 . Past current malignancy , except 1 . Cervical carcinoma Stage 1B less 2 . Noninvasive basal cell squamous cell skin carcinoma 3 . Cancer diagnose duration complete response ( remission ) &gt; 5 year 4 . A history hematologic malignancy excludes subject participation , regardless response . 3 . Recent major surgery within last 28 day . 4 . Significant concurrent , uncontrolled medical condition include , limited , cardiac , renal , hepatic , hematological , gastrointestinal , endocrine , immunodeficiency syndrome , pulmonary , cerebral , psychiatric , neurological disease could affect subject 's safety , impair subject 's reliable participation trial , impair evaluation endpoint , necessitate use medication allow protocol . 5 . Use investigational drug experimental therapy condition NMO within 4 week , 5 pharmacokinetic half live duration biological effect ( whichever longer ) prior screen . 6 . Current participation interventional clinical trial . Participation noninterventional trial require approval protocol investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>NMO</keyword>
	<keyword>NMOSD</keyword>
	<keyword>NMO-IgG</keyword>
	<keyword>Aquaporin-4</keyword>
	<keyword>AQP4</keyword>
	<keyword>anti-AQP4</keyword>
</DOC>